Viewpoint: anti-viral antibodies must be prioritised in the EU coronavirus response Viewpoint: anti-viral antibodies must be prioritised in the EU coronavirus response The European Commission’s work to secure access to potential COVID-19 vaccines is welcome, but other therapies are needed to end the pandemic and negotiations with European manufacturers of anti-viral antibodies should not be further delayed 27 Aug 2020 News